Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanosphere Health SciencesFRA:2CG 14-Day RSI is 49.34 as of Jul. 21, 2026. Among 1,424 Biotechnology companies, Nanosphere Health Sciences ranks worse than 99.93% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
FRA:2CG's 14-Day RSI is ranked worse than 99.93% of 1424
companies
in the Biotechnology industry
Industry Median: 44.785
vs FRA:2CG: 49.34
Nanosphere Health Sciences (FRA:2CG) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Nanosphere Health Sciences 14-Day RSI Related Terms
FRA:2CG vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Nanosphere Health Sciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosphere Health Sciences 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanosphere Health Sciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Nanosphere Health Sciences's 14-Day RSI falls into.
Nanosphere Health Sciences (FRA:2CG) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosphere Health Sciences (FRA:2CG) has a 14-Day RSI of 49.34 as of Jul. 21, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Nanosphere Health Sciences and its competitors. According to the industry distribution chart, Nanosphere Health Sciences ranks #1423 out of 1424 companies in the Biotechnology industry, placing it in the top 99.9%.
Is Nanosphere Health Sciences' 14-Day RSI too high?
Nanosphere Health Sciences' current 14-Day RSI is 49.34. The Biotechnology industry median 14-Day RSI is 44.79. Nanosphere Health Sciences' value of 49.34 is 10.2% above this industry median. Based on the distribution chart, Nanosphere Health Sciences ranks #1423 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nanosphere Health Sciences' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanosphere Health Sciences ranks #1423 out of 1424 companies for 14-Day RSI. This places Nanosphere Health Sciences in the lower half of its industry. The industry median 14-Day RSI is 44.79. Nanosphere Health Sciences' value of 49.34 is 10.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.79, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosphere Health Sciences's current 14-Day RSI of 49.34 is 10.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Nanosphere Health Sciences and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosphere Health Sciences's current 14-Day RSI is 49.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosphere Health Sciences stock overvalued right now?
Nanosphere Health Sciences (FRA:2CG) has a current 14-Day RSI of 49.34. The current 14-Day RSI is 49.34 and 10.2% above the Biotechnology industry median of 44.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Nanosphere Health Sciences (FRA:2CG), the current 14-Day RSI is 49.34 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanosphere Health Sciences Inc is a biotechnology company focused on providing next generation delivery of biologically active compounds through licensing and joint venture arrangements. The Company has developed and is commercializing its patented NanoSphere Delivery System, a nanotechnology platform for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The NanoSphere Delivery System provides improved bioavailability, efficacy, and onset of effect over traditional delivery systems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CG has been successfully added to your 
